BioLineRx Non Current Liabilities Total from 2010 to 2025
| BLRX Stock | USD 3.05 0.14 4.39% |
Non Current Liabilities Total | First Reported 2011-03-31 | Previous Quarter 20.1 M | Current Value 19.3 M | Quarterly Volatility 6.7 M |
Check BioLineRx financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BioLineRx's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.7 M, Interest Expense of 2.6 M or Selling General Administrative of 20.1 M, as well as many indicators such as Price To Sales Ratio of 10.09, Dividend Yield of 0.0 or PTB Ratio of 7.44. BioLineRx financial statements analysis is a perfect complement when working with BioLineRx Valuation or Volatility modules.
BioLineRx | Non Current Liabilities Total |
Latest BioLineRx's Non Current Liabilities Total Growth Pattern
Below is the plot of the Non Current Liabilities Total of BioLineRx over the last few years. It is BioLineRx's Non Current Liabilities Total historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in BioLineRx's overall financial position and show how it may be relating to other accounts over time.
| Non Current Liabilities Total | 10 Years Trend |
|
Non Current Liabilities Total |
| Timeline |
BioLineRx Non Current Liabilities Total Regression Statistics
| Arithmetic Mean | 8,002,116 | |
| Geometric Mean | 2,660,984 | |
| Coefficient Of Variation | 106.40 | |
| Mean Deviation | 7,061,821 | |
| Median | 5,266,045 | |
| Standard Deviation | 8,514,332 | |
| Sample Variance | 72.5T | |
| Range | 23.9M | |
| R-Value | 0.86 | |
| Mean Square Error | 20.5T | |
| R-Squared | 0.74 | |
| Significance | 0.000021 | |
| Slope | 1,534,191 | |
| Total Sum of Squares | 1087.4T |
BioLineRx Non Current Liabilities Total History
About BioLineRx Financial Statements
BioLineRx investors use historical fundamental indicators, such as BioLineRx's Non Current Liabilities Total, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in BioLineRx. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Non Current Liabilities Total | 22.8 M | 24 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Tools for BioLineRx Stock Analysis
When running BioLineRx's price analysis, check to measure BioLineRx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioLineRx is operating at the current time. Most of BioLineRx's value examination focuses on studying past and present price action to predict the probability of BioLineRx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioLineRx's price. Additionally, you may evaluate how the addition of BioLineRx to your portfolios can decrease your overall portfolio volatility.